Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECIRRA: Insulin Resistance Reducing Agents in CABG
NCT02184507Phase 2Completed
- Start
- Jun 2013
- Primary completion
- Mar 2014
01
Overview
Phase 2, randomised, double-blind trial (4 arms). Primary endpoints: Serum glucose at 37 days, Serum insulin at 37 days and 2 more. Started Jun 2013; status: completed.
Beyond the preview
Go deeper on NCT02184507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02184507.